MarketPulse

Dupixent

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron's Dupixent Wins Japan Approval for Rare Skin Disorder

Dupixent receives Japanese marketing authorization for bullous pemphigoid, becoming the first targeted treatment. Study showed 18% remission rate versus 4% for placebo.
SNYREGNmonoclonal antibodyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Dupixent Wins Japan Approval for Rare Autoimmune Disorder, Expanding Sanofi-Regeneron Pipeline

Sanofi and Regeneron's Dupixent secured Japanese regulatory approval for bullous pemphigoid, marking the drug's seventh indication in Japan with superior remission rates versus placebo.
SNYREGNclinical trialDupixent
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Regeneron's Pipeline Depth and Dupixent Dominance Set Stage for Decade of Growth

Regeneron's Dupixent dominance and deep pipeline across weight management, oncology, and rare diseases position the company for sustained growth through the mid-2030s.
REGNbiotechpatent cliff
BenzingaBenzinga··Vandana Singh

FDA Expands Dupixent Approval to Allergic Fungal Rhinosinusitis

FDA approves Dupixent for allergic fungal rhinosinusitis in patients six and older, marking the drug's ninth indication for treating type 2 inflammatory conditions.
SNYREGNFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Sanofi Shares Slide as Hudson Steps Down; Garijo to Lead Post-AGM

Sanofi CEO Paul Hudson steps down February 17; Belén Garijo takes over post-AGM. Stock fell 4.5% on leadership transition announcement amid vaccine sales decline concerns.
SNYREGNstock declineCEO transition